Management of gastrointestinal stromal tumors

Future Oncology

Volumn 9, Issue 2, 2013, Pages 193-206

  Rajendra, Rajeev ^a   Pollack, Seth M ^a   Jones, Robin L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

GIST; imatinib; KIT; regorafenib; sunitinib; surgery; tyrosine kinase inhibitors

Indexed keywords

CRENOLANIB; EVEROLIMUS; GANETESPIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MASITINIB; MOTESANIB; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; REGORAFENIB; RETASPIMYCIN; STEM CELL FACTOR; SU 11548; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB;

ABDOMINAL PAIN; ACUTE HEART FAILURE; ADJUVANT THERAPY; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENTEROCUTANEOUS FISTULA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; INSOMNIA; LIMB ISCHEMIA; LUNG EDEMA; LUNG EMBOLISM; MITOSIS RATE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RESPIRATORY FAILURE; REVIEW; RISK MANAGEMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SUBARACHNOID HEMORRHAGE; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME;

AGE FACTORS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; PROGNOSIS;

EID: 84874081070     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.178     Document Type: Review

References (111)

1. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am. J. Surg. Pathol. 7(6), 507-519 (1983).
2. Macewen EG, Kurzman ID, Rosenthal RC et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl Cancer Inst. 81(12), 935-938 (1989).
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 438(1), 1-12 (2001).
4. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod. Pathol. 13(10), 1134-1142 (2000).
5. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of ckit in human gastrointestinal stromal tumors. Science 279(5350), 577-580 (1998).
6. Cassier PA, Gelderblom H, Stacchiotti S et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/ pigmented villonodular synovitis. Cancer 118(6), 1649-1655 (2011).
7. Corless CL. Assessing the prognosis of gastrointestinal stromal tumors: A growing role for molecular testing. Am. J Clin. Pathol. 122(1), 11-13 (2004).
8. Van Glabbeke M, Verweij J, Casali PG et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for research and treatment of cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J. Clin. Oncol. 23(24), 5795-5804 (2005).
9. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 231(1), 51-58 (2000).
10. Diment J, Tamborini E, Casali P, Gronchi A, Carney JA, Colecchia M. Carney triad: case report and molecular analysis of gastric tumor. Hum. Pathol. 36(1), 112-116 (2005).
11. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and Southwest Oncology Group. J. Clin. Oncol. 26(33), 5360-5367 (2008).
12. Brooks BJ, Bani JC, Fletcher CD, Demeteri GD. Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI571). J Clin. Oncol. 20(3), 870-872 (2002).
13. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 130(10), 1466-1478 (2006).
14. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3(11), 655-664 (2002).
15. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum. Pathol. 33(5), 459-465 (2002).
16. Dumont AG, Rink L, Godwin AK et al. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann. Oncol. 23(5), 1335-1340 (2012).
17. Graadt Van Roggen JF, Van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J. Clin. Pathol. 54(2), 96-102 (2001).
18. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. 152(5), 1259-1269 (1998).
19. Rumessen JJ, Mikkelsen HB, Qvortrup K, Thuneberg L. Ultrastructure of interstitial cells of Cajal in circular muscle of human small intestine. Gastroenterology 104(2), 343-350 (1993).
20. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22(18), 3813-3825 (2004).
21. WHO; International Agency for Research on Cancer. Pathology and Genetics: Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F (Eds). IARC Press, Lyon, France (2002).
22. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of cKIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96(3), 925-932 (2000).
23. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum. Pathol. 33(5), 484-495 (2002).
24. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am. J. Clin. Pathol. 117(2), 188-193 (2002).
25. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607), 708-710 (2003).
26. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42(8), 1093-1103 (2006).
27. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61(22), 8118-8121 (2001).
28. Emile JF, Brahimi S, Coindre JM et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med. Oncol. 29(3), 1765-1772 (2012).
29. Hostein I, Faur N, Primois C et al. BRAF mutation status in gastrointestinal stromal tumors. Am. J. Clin. Pathol. 133(1), 141-148 (2010).
30. Nilsson B, Andersson J, Meis-Kindblom J et al. [GIST-a significantly more common tumor than earlier apprehended. New discoveries on the pathogenesis of GIST yielded new medical treatment]. Lakartidningen 100(11), 930-934, 936-938 (2003).
31. Janeway KA, Liegl B, Harlow A et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 67(19), 9084-9088 (2007).
32. Agaram NP, Laquaglia MP, Ustun B et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin. Cancer Res. 14(10), 3204-3215 (2008).
33. Janeway KA, Albritton KH, Van Den Abbeele AD et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr. Blood Cancer 52(7), 767-771 (2009).
34. Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int. J. Cancer 127(11), 2718-2722 (2010).
35. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J. Intern. Med. 266(1), 43-52 (2009).
36. Chou FF, Eng HL, Sheen-Chen SM. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery 119(2), 171-177 (1996).
37. Crosby JA, Catton CN, Davis A et al. Malignant gastrointestinal stromal tumors of the small intestine. A review of 50 cases from a prospective database. Ann. Surg. Oncol. 8(1), 50-59 (2001).
38. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann. Surg. 215(1), 68-77 (1992).
39. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur. J. Cancer 38(Suppl. 5), S37-38 (2002).
40. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin.Oncol. 24(15), 2325-2331 (2006).
41. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. 33(5), 466-477 (2002).
42. Assi H, Missenard G, Terrier P et al. Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy Phase II trial. Curr. Oncol. 17(6), 23-31 (2010).
43. Zalupski M, Metch B, Balcerzak S et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study. J. Natl Cancer Inst. 83(13), 926-932 (1991).
44. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2phenylaminopyrimidine derivative. Cancer Res. 56(1), 100-104 (1996).
45. Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCRABL, TELABL, and TELPDGFR fusion proteins. Blood 90(12), 4947-4952 (1997).
46. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCRABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344(14), 1038-1042 (2001).
47. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14), 1031-1037 (2001).
48. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A Phase I study. Lancet 358(9291), 1421-1423 (2001).
49. Verweij J, Van Oosterom A, Blay JY et al. Imatinib mesylate (STI571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur. J. Cancer 39(14), 2006-2011 (2003).
50. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26(4), 626-632 (2008).
51. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440), 1127-1134 (2004).
52. Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann. Oncol. 16(4), 566-578 (2005).
53. Gastrointestinal Stromal Tumor MetaAnalysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J. Clin. Oncol. 28(7), 1247-1253 (2010).
54. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 373(9669), 1097-1104 (2009).
55. Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 307(12), 1265-1272 (2012).
56. Eisenberg BL, Harris J, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J. Surg. Oncol. 99(1), 42-47 (2009).
57. Katz D, Segal A, Alberton Y et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 15(6), 599-602 (2004).
58. Bonvalot S, Le Cesne A. [Diagnosis and treatment of gastrointestinal stromal tumours]. Rev. Prat. 56(4), 359-367 (2006).
59. Andtbacka RH, Ng CS, Scaife CL et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann. Surg. Oncol. 14(1), 14-24 (2007).
60. Dematteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann. Surg. 245(3), 347-352 (2007).
61. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann. Surg. 245(3), 341-346 (2007).
62. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J. Surg. Oncol. 93(4), 304-311 (2006).
63. Fiore M, Palassini E, Fumagalli E et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur. J. Surg. Oncol. 35(7), 739-745 (2009).
64. Haller F, Happel N, Schulten HJ et al. Sitedependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors. Mod. Pathol. 20(10), 1103-1111 (2007).
65. Mussi C, Ronellenfitsch U, Jakob J et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann. Oncol. 21(2), 403-408 (2010).
66. Raut CP, Wang Q, Manola J et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann. Surg. Oncol. 17(2), 407-415 (2010).
67. Jones RL, McCall J, Adam A et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur. J. Surg. Oncol. 36(5), 477-482 (2010).
68. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003).
69. Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 20(18), 3898-3905 (2002).
70. Medeiros F, Corless CL, Duensing A et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am. J. Surg. Pathol. 28(7), 889-894 (2004).
71. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3(12), 1001-1010 (2004).
72. Von Bubnoff N, Schneller F, Peschel C, Duyster J. BCRABL gene mutations in relation to clinical resistance of Philadelphiachromosome-positive Lancet 359(9305), 487-491 (2002).
73. Branford S, Rudzki Z, Walsh S et al. Detection of BCRABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (Ploop) are associated with a poor prognosis. Blood 102(1), 276-283 (2003).
74. Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 11(11), 4182-4190 (2005).
75. Tamborini E, Pricl S, Negri T et al. Functional analyses and molecular modeling of two cKit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 25(45), 6140-6146 (2006).
76. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res. 12(6), 1743-1749 (2006).
77. Demetri GD, Wang Y, Wehrle E et al. Imatinib plasma levels are correlated with clinical benefin patients with unresectable/metastatic gastrointestinal stromal tumors. J. Clin. Oncol. 27(19), 3141-3147 (2009).
78. Le Cesne A, Ray-Coquard I, Bui BN et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised Phase 3 trial. Lancet Oncol. 11(10), 942-949 (2010).
79. Norden-Zfoni A, Desai J, Manola J et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 13(9), 2643-2650 (2007).
80. Demetri GD, Van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368(9544), 1329-1338 (2006).
81. George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer 45(11), 1959-1968 (2009).
82. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604), 2011-2019 (2007).
83. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25(13), 1753-1759 (2007).
84. George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial. J Clin Oncol 30(19), 2401-2407 (2012).
85. Demetri GD, Reichardt P, Kang YK, Blay JY et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet doi:10.1016/S0140-6736(12)61857-1 (2012) (Epub ahead of print).
86. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of BcrAbl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 1754(1-2), 3-13 (2005).
87. Prenen H, Guetens G, De Boeck G et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 77(1), 11-16 (2006).
88. White DL, Saunders VA, Dang P et al. OCT1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108(2), 697-704 (2006).
89. Dileo P, Bauer S. Van Den Abbeele A et al. Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST. Presented at: American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 26-28 January 2006 (Abstract 53).
90. Demetri GD, Casali PG, Blay JY et al. A Phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.Clin. Cancer Res. 15(18), 5910-5916 (2009).
91. Montemurro M, Schoffski P, Reichardt P et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur. J. Cancer 45(13), 2293-2297 (2009).
92. Reichardt P, Blay JY, Gelderblom H et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann. Oncol. 23(7), 1680-1687 (2012).
93. Lewis NL, Lewis LD, Eder JP et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J. Clin. Oncol. 27(31), 5262-5269 (2009).
94. Heinrich M, Griffith, D, Mckinley, A, Presnell A, Ramachandran A. The effect of crenolanib (CP868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors. J. Clin.Oncol. 29(Suppl.), Abstract 10012 (2011).
95. Fletcher JA, Fletcher CD, Rubin BP, Ashman LK, Corless CL, Heinrich MC. KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized? Am. J. Pathol. 161(2), 737-738; author reply 738-739 (2002).
96. Schoffski P, Reichardt P, Blay JY et al. A Phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann. Oncol. 21(10), 1990-1998 (2010).
97. Benjamin RS, Schoffski P, Hartmann JT et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer chemother. Pharmacol. 68(1), 69-77 (2011).
98. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8(4), 370-374 (2008).
99. Demetri G, Heinrich, M, Chmielowski B et al. An open-label Phase II study of the Hsp90 inhibitor ganetespib (STA9090) in patients (pts) with metastatic and/or unresectable GIST. Presented at: 2011 American Society of Clinical Onocology Annual Meeting. Chicago, IL, USA, 3-7 June 2011 (Abstract 10011).
100. Hanson BE, Vesole DH. Retaspimycin hydrochloride (IPI504): A novel heat shock protein inhibitor as an anticancer agent. Expert Opin. Investig. Drugs 18(9), 1375-1383 (2009).
101. Park SH, Ryu MH, Ryoo BY et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: A Phase II study of Korean gastrointestinal stromal tumors study group. Invest. New Drugs 30(6), 2377-2383 (2012).
102. Le Cesne A, Blay JY, Bui BN et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur. J. Cancer 46(8), 1344-1351 (2010).
103. Joensuu H, De Braud F, Coco P et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann. Oncol. 19, 173-177 (2008).
104. Richter S, Pink D, Hohenberger P et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. ASCO Meeting Abstracts 28(Suppl. 15), 10038 (2010).
105. Demetri G, Le Cesne A, von Mehren M et al. Final results from a Phase III study of IPI-504 retaspimycin hydrochloride) versus placebo in patients with gastrointestinal stromal tumors (GIST) following failure of tyrosine kinase inhibitor (TKI) therapies. ASCO Gastrointestinal Cancers Symposium Meeting Abstracts 28(Suppl. 15), 64 (2010).
106. Hanson BE, Vesole DH. Retaspimycin hydrochloride (IPI504): A novel heat shock protein inhibitor as an anticancer agent. Expert Opin. Investig. Drugs 18(9), 1375-1383 (2009).
107. Park SH, Ryu MH, Ryoo BY et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: A Phase II study of Korean gastrointestinal stromal tumors study group. Invest. New Drugs 30(6), 2377-2383 (2012).
108. Le Cesne A, Blay JY, Bui BN et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur. J. Cancer 46(8), 1344-1351 (2010).
109. Joensuu H, De Braud F, Coco P et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann. Oncol. 19, 173-177 (2008).
110. Richter S, Pink D, Hohenberger P et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. ASCO Meeting Abstracts 28(Suppl. 15), 10038 (2010).
111. Demetri G, Le Cesne A, von Mehren M et al. Final results from a Phase III study of IPI-504 retaspimycin hydrochloride) versus placebo in patients with gastrointestinal stromal tumors (GIST) following failure of tyrosine kinase inhibitor (TKI) therapies. ASCO Gastrointestinal Cancers Symposium Meeting Abstracts 28(Suppl. 15), 64 (2010).